Erythropoietic Protoporphyria with Multiple Organ Failure in Children：a Case Report and Literature Review

doi:10.12114/j.issn.1007-9572.2021.01.014

Abstract

Abstract: Erythropoietic protoporphyria is a rare disease characterized by impaired activity of ferrochelatase caused by FECH genetic mutations. This study reviewed the clinical data and results of gene analysis of a child with erythropoietic protoporphyria and relevant studies，and discussed the features of this disease and mutation sites of pathogenic genes，in order to improve clinical understanding of erythropoietic protoporphyria. Clinical attention should be paid to warning signs of erythropoietic protoporphyria，such as recurring rashes in the parts of the skin exposed to sunlight，especially accompanied with abdominal pain and liver damage，FECH gene test is helpful for the diagnosis of the disease.

Key words: Protoporphyria, erythropoietic；Erythropoietic protoporphyria；Abdominal pain；Multiple organ failure；Photoallergy；FECH gene

摘要： 红细胞生成性原卟啉病是一种罕见病，其病因是患者体内基因突变（FECH基因）引起的亚铁螯合酶活性受损。本文通过回顾1例红细胞生成性原卟啉病患儿的临床资料以及相关基因的检测结果，并进行文献复习，探讨红细胞生成性原卟啉病的临床特点及致病基因的突变位点，以提高临床医生对该病的认识。对临床上反复曝光部位的皮疹，尤其伴有腹痛、肝损害时，应警惕红细胞生成性原卟啉病，FECH基因检测有助于该病的诊断。

关键词: 原卟啉病, 红细胞生成性；红细胞生成性原卟啉病；腹痛；多器官功能衰竭；光变态反应；FECH基因

MA Chunmiao,YU Xinyou,LU Biao, et al. Erythropoietic Protoporphyria with Multiple Organ Failure in Children：a Case Report and Literature Review　[J]. Chinese General Practice, 2021, 24(32): 4160-4164. DOI: 10.12114/j.issn.1007-9572.2021.01.014.
马春苗,于辛酉,陆彪等. 儿童红细胞生成性原卟啉病多器官功能衰竭一例并文献复习[J]. 中国全科医学, 2021, 24(32): 4160-4164. DOI: 10.12114/j.issn.1007-9572.2021.01.014.

References

［1］MAGNUS I A，JARRETT A，PRANKERD T A J，et al. Erythropoietic protoporphyria a new Porphyria syndrome with solar urticaria due to protoporphyrin?mia［J］. Lancet，1961，278（7200）：448-451. DOI：10.1016/S0140-6736（61）92427-8.
［2］KHALILI M J，FARAHMAND F，HIRBOD-MOBARAKEH A，et al. Erythropoietic protoporphyria and early onset of cholestasis［J］. Turk J Pediatr，2012，54（6）：645-650.
［3］丛林，王文岭，夏志宽，等. 红细胞生成性原卟啉病一例并文献复习［J］. 实用皮肤病学杂志，2012，5（3）：129-131，137.
CONG L，WANG W L，XIA Z K，et al. Erythropoietic protoporphyria：a case report and literature review［J］. J Pract Dermatol，2012，5（3）：129-131，137.
［4］MIZAWA M，MAKINO T，NAKANO H，et al. Erythropoietic protoporphyria in a Japanese population［J］. Acta Derm Venereol，2019，99（7）：634-639. DOI：10.2340/00015555-3184.
［5］REISENAUER A K，SOON S L，LEE K K，et al. Erythropoietic protoporphyria presenting with liver failure in adulthood［J］. Dermatol Basel Switz，2005，210（1）：72-73. DOI：10.1159/000081490.
［6］WHATLEY S D，MASON N G，HOLME S A，et al. Molecular epidemiology of erythropoietic protoporphyria in the U.K［J］. Br J Dermatol，2010，162（3）：642-646. DOI：10.1111/j.1365-2133.2010.09631.x.
［7］RICHARDS S，AZIZ N，BALE S，et al. Standards and guidelines for the interpretation of sequence variants：a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology［J］. Genet Med，2015，17（5）：405-424. DOI：10.1038/gim.2015.30.
［8］BHARATI A，BADMINTON M N，WHATLEY S D，et al. Late-onset erythropoietic protoporphyria in association with haematological malignancy［J］. Clin Exp Dermatol，2006，31（5）：668-670. DOI：10.1111/j.1365-2230.2006.02179.x.
［9］MICHAELLE B D，DEL R Q，MOBINI N，et al. Erythropoietic protoporphyria：a case report and literature review［J］. J Clin Aesthet Dermatol，2010，3（7）：44-48.
［10］ALAGAPPAN U，PRAMONO Z A D，CHONG W S. Ferrochelatase gene mutation in Singapore and a novel frame-shift mutation in an Asian boy with erythropoietic protoporphyria［J］. Int J Dermatol，2017，56（3）：272-276. DOI：10.1111/ijd.13418.
［11］曹丽丽，董漪，储芳，等. 以肝衰竭为主要表现的红细胞生成性原卟啉病1例报告［J］. 临床肝胆病杂志，2018，34（9）：1975-1978.
CAO L L，DONG Y，CHU F，et al. Liver failure as the main manifestation of erythropoietic protoporphyria：a case report［J］. Journal of Clinical Hepatology，2018，34（9）：1975-1978.
［12］吴梅，于长平，卢宪梅. 红细胞生成性原卟啉病2例［J］. 中国麻风皮肤病杂志，2007，23（5）：427-428.
［13］PAGANO M B，HOBBS W，LINENBERGER M，et al. Plasma and red cell exchange transfusions for erythropoietic protoporphyria：a case report and review of the literature［J］. J Clin Apher，2012，27（6）：336-341. DOI：10.1002/jca.21249.
［14］FRANK J，NELSON J，WANG X，et al. Erythropoietic protoporphyria：identification of novel mutations in the ferrochelatase gene and comparison of biochemical markers versus molecular analysis as diagnostic strategies［J］. J Investig Med，1999，47（6）：278-284.
［15］WHATLEY S D，MASON N G，HOLME S A，et al. Molecular epidemiology of erythropoietic protoporphyria in the U.K［J］. Br J Dermatol，2010，162（3）：642-646. DOI：10.1111/j.1365-2133.2010.09631.x.
［16］BALWANI M. Erythropoietic Protoporphyria and X-Linked Protoporphyria：pathophysiology，genetics，clinical manifestations，and management［J］. Mol Genet Metab，2019，128（3）：298-303. DOI：10.1016/j.ymgme.2019.01.020.
［17］GOUYA L，PUY H，ROBREAU A M，et al. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH［J］. Nat Genet，2002，30（1）：27-28. DOI：10.1038/ng809.
［18］WHATLEY S D，DUCAMP S，GOUYA L，et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without Anemia or iron overload［J］. Am J Hum Genet，2008，83（3）：408-414. DOI：10.1016/j.ajhg.2008.08.003.
［19］NAKANO H，NAKANO A，TOYOMAKI Y，et al. Novel ferrochelatase mutations in Japanese patients with erythropoietic protoporphyria：high frequency of the splice site modulator IVS3-48C polymorphism in the Japanese population［J］. J Investig Dermatol，2006，126（12）：2717-2719. DOI：10.1038/sj.jid.5700456.
［20］WHATLEY S D，MASON N G，KHAN M，et al. Autosomal recessive erythropoietic protoporphyria in the United Kingdom：prevalence and relationship to liver disease［J］. J Med Genet，2004，41（8）：e105. DOI：10.1136/jmg.2003.016121.
［21］PARKER M，CORRIGALL A V，HIFT R J，et al. Molecular characterization of erythropoietic protoporphyria in South Africa［J］. Br J Dermatol，2008，159（1）：182-191. DOI：10.1111/j.1365-2133.2008.08580.x.
［22］FONTANELLAS A，áVILA M A，ANDERSON K E，et al. Current and innovative emerging therapies for porphyrias with hepatic involvement［J］. J Hepatol，2019，71（2）：422-433. DOI：10.1016/j.jhep.2019.05.003.
［23］TRAUNER M A，RUBEN B S，LYNCH P J. Segmental tuberous sclerosis presenting as unilateral facial angiofibromas［J］. J Am Acad Dermatol，2003，49（2 suppl case reports）：S164-166. DOI：10.1067/mjd.2003.146.
［24］BENTLEY D P，MEEK E M. Clinical and biochemical improvement following low-dose intravenous iron therapy in a patient with erythropoietic protoporphyria［J］. Br J Haematol，2013，163（2）：289-291. DOI：10.1111/bjh.12485.
［25］BALWANI M，WANG B，ANDERSON K E，et al. Acute hepatic porphyrias：recommendations for evaluation and long-term management［J］. Hepatology，2017，66（4）：1314-1322. DOI：10.1002/hep.29313.
［26］BISSELL D M，ANDERSON K E，BONKOVSKY H L. Porphyria［J］. N Engl J Med，2017，377（9）：862-872. DOI：10.1056/nejmra1608634.
［27］师杰，李晓青，卢朝辉. 红细胞生成性原卟啉病并发肝脏病变三例临床病理特征观察［J］. 中华病理学杂志，2017，46（10）：704-707. DOI：10.3760/cma.j.issn.0529-5807.2017.10.009.
SHI J，LI X Q，LU C H. Clinicopathological characteristics of three cases of erythropoietic protoporphyria complicated with hepatic lesions［J］. Chinese Journal of Pathology，2017，46（10）：704-707. DOI：10.3760/cma.j.issn.0529-5807.2017.10.009.
［28］HONDA Y，KAWAKAMI Y，KAN H，et al. A second attack of cholestasis associated with erythropoietic protoporphyria was successfully treated by plasma exchange and blood transfusion［J］. Clin J Gastroenterol，2014，7（4）：333-337. DOI：10.1007/s12328-014-0501-7.
［29］LOCK G，HOLSTEGE A，MUELLER A R，et al. Liver failure in erythropoietic protoporphyria associated with choledocholithiasis and severe post-transplantation polyneuropathy［J］. Liver，1996，16（3）：211-217. DOI：10.1111/j.1600-0676.1996.tb00730.x.
［30］李晓青，师杰，赖雅敏，等. 4例以黄疸为主要表现的红细胞生成性原卟啉病临床、病理及遗传学分析［J］. 临床肝胆病杂志，2017，33（7）：1332-1335.
LI X Q，SHI J，LAI Y M，et al. Clinical and pathological and genetic analysis of 4 cases of erythropoietic protoporphyria with jaundice as the main manifestation［J］. Journal of Clinical Hepatology，2017，33（7）：1332-1335.